AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 28, 2024

The new research centers on the protein contactin-4 (CNTN4) – thought to play a role in neuronal network […] There are a lot of connected, moving biological parts in our brains, which makes the study of brain diseases particularly challenging.

Protein 199

Protein Research Clinical Trials Clinical Trials 199

Pharmaceutical Technology

JULY 20, 2022

Researchers at Gladstone Institutes and UC San Francisco (UCSF) have discovered in a study that bromodomain and extraterminal (BET) proteins are vital for the body to fight Covid-19 infection. . The research also found that BET proteins play two distinct roles in affecting how the SARS-CoV-2 virus interacts with human cells. .

Protein 278

Protein Scientist Gene DNA 278

Pharmaceutical Technology

FEBRUARY 6, 2023

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263

Protein Research Antibody Immune Response 263

Pharmaceutical Technology

AUGUST 22, 2024

Discover Larimar Therapeutics' groundbreaking patent on measuring frataxin (FXN) protein activity. Learn how this innovative method could impact research and therapies.

Protein 130

Protein Research 130

Bio Pharma Dive

JULY 24, 2023

Regulators are recognizing mass spectrometry as a powerful tool in Host Cell Protein analysis. Are you ready to implement HCP-MS?

Protein 246

Protein Regulation 246

Bio Pharma Dive

MARCH 22, 2023

Armed with a $50 million Series A round, the startup is building off of research from a lab run by protein engineering pioneer Jim Wells.

Protein 357

Protein Engineer Research 357

Bio Pharma Dive

MARCH 27, 2023

A closely watched meeting showed the FDA’s own external advisers think that effects on this protein, known as neurofilament, could be enough to warrant conditional approval of certain drugs.

Protein 328

Protein Drugs 328

Pharmaceutical Technology

AUGUST 30, 2024

GlobalData’s report assesses the drugs in the Gap Junction Beta 2 Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Bio Pharma Dive

AUGUST 25, 2021

The pharma has struck its second research pact focused on drugs that break down harmful proteins in as many years, this time with California biotech Lycia Therapeutics.

Protein 287

Protein Drugs Research 287

Pharmaceutical Technology

AUGUST 30, 2024

GlobalData’s report assesses the drugs in the Dynamin Like 120 kDa Protein Mitochondrial pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

APRIL 18, 2024

Discover the groundbreaking multi-domain active protein patented by Huadong Medicine Co Ltd for treating metabolic diseases. With increased efficacy and simplified preparation process, this protein is set to revolutionize existing treatments.

Protein 130

Protein Medicine 130

Pharmaceutical Technology

APRIL 22, 2024

Discover Arvinas Inc's groundbreaking patent for compounds targeting tau protein degradation, offering hope for Alzheimer's and other neurodegenerative diseases. Learn about the promising results and potential therapeutic value of this innovative treatment.

Protein 130

Protein 130

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 7, 2024

Scientists have now demonstrated how stimulating high-frequency brain waves in mice can clear out the amyloid protein clumps associated with Alzheimer’s. Could Alzheimer’s disease one day be treated by flashes of light and clicks of sound?

Protein 182

Protein Scientist Research Clinical Trials 182

Bio Pharma Dive

AUGUST 2, 2022

It’s the second deal in as many years between AbbVie and Sosei Heptares, which together have been trying to develop drugs that target so-called G protein-coupled receptors.

Protein 273

Protein Development Drugs 273

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Bromodomain Containing Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Containment 130

Containment Protein Development Drugs 130

BioPharma Reporter

JUNE 26, 2024

ELRIG UK, a leading organization in the drug discovery community, has partnered with The Protein Society (TPS) to host a groundbreaking conference on âProtein Sciences in Drug Discoveryâ.

Protein 97

Protein Drugs Development 97

Roots Analysis

SEPTEMBER 9, 2024

Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

Pharmaceutical Technology

MARCH 29, 2024

Discover the groundbreaking patent by Yield10 Bioscience Inc for a genetically engineered oilseed plant expressing a plant protein, revolutionizing biotechnology in agriculture.

Genetic Engineering 130

Genetic Engineering Engineer Genetics Protein 130

Bio Pharma Dive

JUNE 14, 2023

The alliance is Astellas’ second recent partnership involving protein degraders, an emerging area of drug research the company has made a focus in recent years.

Protein 176

Protein Drugs Research 176

Pharmaceutical Technology

JUNE 10, 2024

Discover Cue Biopharma Inc's innovative patent for treating cancer with immune checkpoint inhibitors and protein compositions targeting specific epitopes. Enhance cancer treatment efficacy with this groundbreaking approach.

Protein 130

Protein 130

Pharmaceutical Technology

MARCH 26, 2024

Discover Innovent Biologics' groundbreaking patent for novel proteins with heterodimeric antibody Fc, revolutionizing antibody engineering and drug development.

Protein 130

Protein Engineer Antibody Development 130

Pharmaceutical Technology

MARCH 28, 2024

Pharmaceutical Technology has listed the leading protein and peptide synthesis solutions and suppliers. Download for free here.

Protein 130

Protein Manufacturing 130

Pharmaceutical Technology

MARCH 26, 2024

Discover how Arcturus Therapeutics' patent for a modified human OTC protein revolutionizes OTC deficiency treatment with codon optimized mRNA sequences.

Protein 130

Protein 130

Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.

Protein 130

Protein Development Licensing Licensing 130

Pharmaceutical Technology

SEPTEMBER 18, 2023

The ability to detect host-cell proteins in bioprocessing streams is a vital tool in pharmaceutical firms' product purification arsenal

Protein 130

Protein Production 130

Pharmaceutical Technology

APRIL 17, 2024

Discover the groundbreaking patent by TCR2 Therapeutics Inc for T-cell receptor fusion proteins targeting tumor cell antigens. Revolutionizing disease treatment, including cancer, with engineered T cells expressing TFPs.

Protein 130

Protein Engineer 130

Bio Pharma Dive

JANUARY 27, 2022

Backed by some of biotech's most powerful investors, Septerna is looking to usher in the next chapter of medicines that act on G protein-coupled receptors.

Protein 318

Protein Medicine Drugs 318

Bio Pharma Dive

JULY 28, 2022

Vicinitas and its protein-stabilizing research have attracted $65 million from a group of investors that includes a16z, Deerfield and GV.

Protein 261

Protein Research 261

Pharmaceutical Technology

JULY 25, 2023

Astellas Pharma has entered a research partnership and licence agreement with PeptiDream for the discovery of new targeted protein degraders.

Protein 130

Protein Research 130

Bio Pharma Dive

DECEMBER 6, 2022

Entact Bio aims to develop medicines that can enhance helpful proteins, rather than block harmful ones, a twist on the usual drugmaking playbook.

Protein 209

Protein Medicine Development 209

pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins. These regions are critical for optimal interactions between proteins.

Protein 127

Protein Gene Bioassay DNA 127

BioSpace

NOVEMBER 28, 2023

In a deal with Tokyo-based PRISM BioLab, Eli Lilly will gain access to the Japanese biotech’s proprietary platform to develop small molecule inhibitors of protein-protein interactions.

Protein 88

Protein Development 88

pharmaphorum

APRIL 11, 2024

Novartis accelerates its protein degrader programmes by licensing a phase 3-ready prostate cancer candidate from Arvinas in a deal worth over $1 billion

Protein 115

Protein Licensing Licensing 115

Pharmaceutical Technology

DECEMBER 7, 2023

GlobalData’s report assesses the drugs in the Cholesteryl Ester Transfer Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase JAK1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Myc Proto Oncogene Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 130

Protein Development Drugs 130

Pharmaceutical Technology

APRIL 17, 2024

Discover a groundbreaking method for treating cancer with mutant RAS proteins using Plinabulin. Learn about the patent's innovative approach targeting NRAS, HRAS, and KRAS mutations in various cancers.

Protein 130

Protein 130